<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1251">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734860</url>
  </required_header>
  <id_info>
    <org_study_id>AMG-COV-201</org_study_id>
    <nct_id>NCT04734860</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms</brief_title>
  <official_title>A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety, pharmacokinetic (PK) profile and efficacy of a single&#xD;
      injection of COVI-AMG in outpatient adults with mild COVID-19 symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind study designed to investigate the safety,&#xD;
      pharmacokinetic (PK) profile and efficacy of a single injection of COVI-AMG in outpatient&#xD;
      adults with mild COVID-19 symptoms. Subjects will be followed for approximately 70 days post&#xD;
      dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have remained out of the hospital or emergency room through Day 29</measure>
    <time_frame>Randomization to Day 29</time_frame>
    <description>Proportion of subjects who have remained out of the hospital or emergency room through Day 29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load reduction from baseline to Day 8, 15, 29, 43, and 70</measure>
    <time_frame>Randomization to Day 8, 15, 29, 43, 70</time_frame>
    <description>Viral load reduction from baseline to Day 8, 15, 29, 43, and 70 as assessed by nasopharyngeal RT-PCR test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have remained out of the hospital or emergency room through Day 43 and 70</measure>
    <time_frame>Randomization to Day 43 and Day 70</time_frame>
    <description>Proportion of subjects who have remained out of the hospital or emergency room through Day 43 and 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have 50%, 70%, and 90% reduction in PRO instrument score</measure>
    <time_frame>Randomization to Day 15, 29, 43</time_frame>
    <description>Proportion of subjects who have 50%, 70%, and 90% reduction in PRO instrument score from baseline at Day 15, 29, and 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Randomization through study completion at Day 70</time_frame>
    <description>For subjects who have a fever at randomization, time to resolution of the fever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVI-AMG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 40 mg, 100 mg, or 200 mg of COVI-AMG will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single injection of placebo will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-AMG</intervention_name>
    <description>COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)</description>
    <arm_group_label>COVI-AMG</arm_group_label>
    <other_name>STI-2020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluent solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive for COVID-19 by an approved antigen test&#xD;
&#xD;
          -  Mild symptoms consistent with a COVID-19 viral infection&#xD;
&#xD;
          -  Willing and able to comply with all planned study procedures and be available for all&#xD;
             study visits and follow-up as required by the protocol&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of moderate COVID-19 per FDA severity categorization&#xD;
&#xD;
          -  Pregnant or lactating and breast feeding or planning on either during the study&#xD;
&#xD;
          -  Has a documented infection other than COVID-19&#xD;
&#xD;
          -  Has received a COVID-19 vaccine&#xD;
&#xD;
          -  Has participated, or is participating, in a clinical research study evaluating&#xD;
             COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or&#xD;
             intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the&#xD;
             investigational product (whichever is longer) prior to the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD</last_name>
    <phone>(858) 203-4100</phone>
    <phone_ext>4146</phone_ext>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

